Apheresis, graft composition, and engraftment
| . | Median (range) . |
|---|---|
| Mobilization: no. of apheresis + back-up* | 2 (2-7) |
| CD34-selected grafts | |
| CD34+ cells × 106/kg | 4.02 (2.36-8.6) |
| CD3+ cells × 104/kg; n = 22 | 1.86 (0-25.2) |
| CD34 purity (%) | 91 (55-99) |
| Engraftment after transplantation | |
| Days to neutrophil count above 500/μL† | 9 (7-13) |
| Days to platelet count above 20 000/μL‡ | 11 (7-25) |
| . | Median (range) . |
|---|---|
| Mobilization: no. of apheresis + back-up* | 2 (2-7) |
| CD34-selected grafts | |
| CD34+ cells × 106/kg | 4.02 (2.36-8.6) |
| CD3+ cells × 104/kg; n = 22 | 1.86 (0-25.2) |
| CD34 purity (%) | 91 (55-99) |
| Engraftment after transplantation | |
| Days to neutrophil count above 500/μL† | 9 (7-13) |
| Days to platelet count above 20 000/μL‡ | 11 (7-25) |
Minor complications observed infrequently during mobilization included edema, increased skin tightness, erythema, and arthralgias, but these resolved after G-CSF was stopped. All grafts were collected with a single course of G-CSF except for 1 patient who had discontinued mycophenolate mofetil immediately before starting collection of peripheral blood stem cells.
First of 3 consecutive days with an absolute neutrophil count above 500/μL.
First of 3 consecutive days with a platelet count above 20 000/μL or an increase in platelet count independent of platelet transfusions.